Skip to content
Advertisement

This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi. Leqembi, the first drug to show that it slows Alzheimer’s, was approved by the U.S. Food and Drug Administration in early January 2023, but treatment for most patients is still several months away. Two big factors behind the slow debut, according to experts, are scant insurance coverage and a long setup time needed by many health systems. (Eisai via AP, File)

This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi. Leqembi, the first drug to show that it slows Alzheimer’s, was approved by the U.S. Food and Drug Administration in early January 2023, but treatment for most patients is still several months away. Two big factors behind the slow debut, according to experts, are scant insurance coverage and a long setup time needed by many health systems. (Eisai via AP, File)

Featured Photo Galleries

01-Army parade.png

Military parade celebrates Army’s 250th

Cheers and chants rang out Saturday from a crowd of thousands as soldiers manned modern and historic tanks and aircraft for the Army’s 250th anniversary celebration in the District.

20250330 Sabatini-Caps-Sabres 001.jpg

Ovi scores goal 890, Caps lose to Sabres 8-5

Alexander Ovechkin scored goal number 890, but the Washington Capitals fell short, losing to the visiting Buffalo Sabres Sunday afternoon 8-5 at Capital One Arena in Washington D.C., March 30, 2025 (Photos for the Washington Times.)